Introduction
Observational data suggest that inadequate vitamin D status is associated with an increased risk of fracture, cancer, and other chronic diseases (1) (2) (3) (4) . Although the definition of an adequate serum concentration remains controversial (12 ng/mL) (5, 6) , it has been argued that one-quarter of Americans have inadequate serum concentrations of 25- 
hydroxyvitamin D [25(OH)D]
''a majority of the population is meeting its needs for vitamin D'' (7) .
Many factors are known to be associated with serum 25(OH)D concentrations, including sun exposure, BMI, skin pigmentation, medications, and comorbidities (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , but, to our knowledge, there is limited evidence on a few factors that may affect the magnitude of serum response to cholecalciferol supplementation, e.g., baseline serum 25(OH)D, BMI, age, calcium intake, and season (27, 28) . The NAM provides intake recommendations by age and sex, but it is unclear whether supplementation should be varied according to vitamin D status, weight, or other factors (7) . In addition, although common genetic variants have been associated with circulating serum 25(OH)D concentrations in genome-wide association studies (29, 30) , their role in affecting the magnitude of serum response to supplementation is also less clear (31) (32) (33) .
In this study, we report the results of analyses of the potential impact of a large number of personal, medical, environmental, lifestyle, and genetic factors on the serum 25(OH)D concentration response to 1 y of oral supplementation with 1000 IU cholecalciferol/d during a multicenter, randomized, placebocontrolled colorectal adenoma chemoprevention trial.
Methods
As described previously (34) , we conducted a randomized, double-blind, placebo-controlled trial (NCT00153816) to test the effects of daily supplementation with 1000 IU cholecalciferol and/or 1200 mg elemental calcium (as calcium carbonate) on large-bowel adenoma recurrence. From May 2004 through July 2008, we recruited participants from 11 centers in the continental United States and Puerto Rico. Participants aged 45-75 y were eligible for enrollment if they had $1 large-bowel adenoma removed and no adenomas remaining after a complete colonoscopic surveillance examination within 4 mo of enrollment. Participants had no familial colorectal cancer syndromes, no history of serious gastrointestinal disease, no serious health concerns that might jeopardize several years of participation in the trial, and no contraindications to, or medical indications for, vitamin D or calcium supplementation.
Participants provided detailed information at enrollment on health, medications, and behavioral factors, such as sun exposure and exercise [International Physical Activity Questionnaire, Short Form (35) ], and completed the Block Brief 2000 FFQ (Nutritionquest). They were counseled by study coordinators to help them avoid consuming >1200 mg Ca and 400 IU vitamin D/d in their food during the study. Participants also agreed to avoid taking vitamin D or calcium supplements other than those provided for the trial, but because vitamin D use in the community gained popularity, the protocol was amended to promote participant retention. From April 2008 onward, if personal supplements #1000 IU vitamin D and/or 400 mg elemental calcium were reported as being taken, these were permitted in addition to the study pills. For those who wished to take a multivitamin during the study, we provided one that lacked calcium and vitamin D. Blood drawn at enrollment and 1 y after random assignment (mean of 14.5 mo after the baseline blood draw) was tested for 25(OH)D with the use of a Gamma-B 25-Hydroxy Vitamin D Liquid-Phase RIA kit (IDS) in laboratory processes monitored through the international Vitamin D External Quality Assessment Scheme. In addition, we genotyped single-nucleotide polymorphisms (SNPs) in selected genes related to vitamin D metabolism, as described previously (31) : genomic DNA was isolated from buffy coat samples by BioServe Biotechnologies with the use of DNAQuiK (36) . Genotyping was conducted by KBioscience with the use of KASP technology (37); or by Genome Quebec Innovation Center with the use of Sequenom iPLEX Gold (38) or predesigned TaqMan assays (rs228570 and rs10766197) (39) .
After a placebo run-in phase of 56-84 d, eligible participants who reported taking $80% of run-in study pills were randomly assigned, provided that their baseline serum 25(OH)D concentration was $12 ng/mL. Participants were randomly assigned in a modified 2 3 2 factorial design stratified by study center, sex, and surveillance interval to 1 of 4 study arms: daily 1000 IU cholecalciferol, 1200 mg Ca as carbonate, both, or placebo. Women with concerns about osteoporosis who declined to forego calcium supplementation were randomly assigned to calcium alone or calcium with vitamin D. Tablets for the study were prepared and tested according to the FDAÕs guidelines for Good Manufacturing Practices. Trained study coordinators interviewed randomly assigned participants by telephone biannually to document changes in health and medications and ascertain self-reported adherence to study-pill intake. Medications were classified according to their constituent drug groups (e.g., loop or thiazide diuretic), but for logistical reasons, drug doses and adherence were not considered in this analysis. Participation in the trial continued through the next surveillance colonoscopy after 3 or 5 y, a surveillance interval determined by each participantÕs medical provider. All candidate variables that were examined are shown in Supplemental Table 1 .
All participants provided written informed consent; the research was approved by the Committee for the Protection of Human Subjects at Dartmouth College and by institutional review boards at each clinical center.
In secondary analyses, we analyzed data from all participants for whom we had a baseline serum 25(OH)D concentration to identify factors associated with serum concentrations at enrollment. We identified potential predictors of serum 25(OH)D concentrations from published research, and used this information to inform our selection of variables for analysis. To explore associations of potential exposures with baseline serum 25(OH)D concentrations, we used linear regression models. Variables with a univariate P < 0.05 were carried forward to the multiple linear regression analysis. The general strategy for modeling included 2 stages: 1) Potential predictors were considered in groups of similar factors, including demographic, sun-related, behavioral, health, medication-related, and nutritional. The best model was obtained within each group by including all variables and then removing the one with the largest P value > 0.05. The model was then refitted and the process repeated until all variables remaining had P < 0.05, giving the best model. 2) All variables from the best group models were entered simultaneously into a further model, and the same procedure was used to reduce the variables to a set of variables that were all significant with P < 0.05, giving the final best model. The 25(OH)D data were positively skewed and were log transformed for analysis to fulfill the distributional assumptions.
With the use of the same modeling strategy, we next examined factors influencing the serum response to vitamin D supplementation in an intention-to-treat analysis of randomly assigned participants for whom we knew both baseline and year 1 serum concentrations. The outcome variable was the logarithm of year 1 serum 25(OH)D concentration; the potential predictors included baseline serum 25(OH)D concentration and randomly assigned treatment group (vitamin D or placebo). The rationale for this analysis approach was to adjust the year 1 serum concentration for baseline serum 25(OH)D concentration and test the effect of each factor on year 1 serum 25(OH)D concentration while removing the effect of regression to the mean. Effects of each factor on response to vitamin D supplementation were tested by fitting the interaction between that factor and the treatment variable. Estimates represent the percentage increase in serum 25(OH)D from baseline associated with supplementation; these are presented separately for individuals in each category of the variable (e.g., in men and women). Statistical significance was assessed with likelihood ratio tests. Because serum 25(OH)D concentration was log transformed, estimated effects are ratios of geometric means, which are expressed as the percentage differences in final serum 25(OH)D concentration between those receiving vitamin D and those receiving placebo. To assist in interpreting the proportional effects, we also calculated the equivalent changes in absolute serum 25(OH)D concentration for participants with median baseline serum 25(OH)D who had increases of 20%, 25%, 30%, 35%, and 40%. In the final model, we included terms for the main effects of the stratification factors: study center, colonoscopy surveillance interval, study arm, and sex.
We conducted exploratory analyses of the effects of medications by adding each separately to the final model, whether or not it was significant in univariate analyses. This was done to provide information systematically on each medication, even though, because of power issues, most had been excluded from the final model. We also defined optimal adherence as the self-reported intake of $80% of study pills, on average, over the entire study period, no personal vitamin D supplementation, and no gaps in pill intake of >7 d. To assess the potential impact of adherence on these results, we repeated the analyses on the subgroup of optimally adherent participants.
In a simple exercise, we classified participants at baseline and year 1 into categories of deficiency (<12 ng/mL), inadequacy (12 to <20 ng/mL), and adequacy ($20 ng/mL) in order to describe changes in the categories of vitamin D sufficiency in those treated with vitamin D or placebo (7) . We restricted this analysis to participants who had not been taking vitamin D supplements at baseline, because only in those participants would the change in serum 25(OH)D be unaffected by the study requirement to stop those supplements at enrollment.
Finally, we genotyped 41 SNPs in selected genes involved in the vitamin D and/or calcium metabolism pathways [selected previously (31) ] to assess their effects on the final model. Population stratification can lead to spurious associations between genetic markers and disease phenotypes because of subpopulation heterogeneity in allele frequencies and disease rates (40) ; to address this concern, a common statistical approach is to restrict genetic analyses to a single ethnic or racial group. We restricted these analyses to our largest subgroup, non-Hispanic whites, and then developed new multivariable models for baseline serum 25(OH)D concentrations and for serum response to 1000 IU cholecalciferol supplementation with the use of the approach described previously. All 41 SNPs were analyzed univariately with the use of an additive model. For SNPs that were associated with serum 25(OH)D baseline concentrations or follow-up changes at P < 0.05, correlations among them were explored, and for those SNPs in high linkage disequilibrium, defined as r 2 > 0.95, only 1 SNP was included in the group SNP model. We then added to the final model all SNPs that remained significant in the group model after backward elimination. For serum response, we also assessed genetic variant associations within the optimally adherent subgroup. Analyses were performed with the use of SAS software version 9.3 and Stata software version 12.
Results
Of 19,083 individuals who were potentially eligible for the trial, 2813 were enrolled, 2753 had baseline serum 25(OH)D measured, 2259 were randomly assigned, and 2187 were included in the response analysis ( Figure 1 ). The mean baseline serum 25(OH)D concentration for all 2753 enrollees was (mean 6 SD) 23.9 6 8.6 ng/mL. At enrollment, 54% of participants had been taking vitamin D supplements and 56% had been taking calcium supplements; they were asked (and agreed) to stop doing so. Subsequently, 107 of 2186 (4.9%) reported taking any personal vitamin D supplements up to 1000 IU/d between random assignment and year 1. Adequate serum 25(OH)D concentrations (i.e., $20 ng/mL) (7) were seen at baseline in 69% of those taking supplements before enrollment and 54% of those not taking supplements ( Table 1) . Mean concentrations ranged from 24.8 ng/mL in whites to 18.1 ng/mL in blacks, with the highest concentrations during the summer and fall, and a downward trend with increasing BMI ( Table 2) .
At baseline, the final multivariable model incorporated 17 factors that were significantly associated with serum 25(OH)D concentration, including demographic, sun-related, healthrelated, behavioral, and nutritional factors; those factors explained 32% of the variability in baseline serum 25(OH)D in 2753 individuals (Table 2) . Several medications were associated with baseline serum 25(OH)D concentrations in univariate analyses; in multivariable models, current or former users of hormone replacement therapy had higher serum 25(OH)D concentrations (P = 0.005), and oral corticosteroid users had lower concentrations (P = 0.02). When we tested all medications (even if not significant in univariate analyses) by adding each to the final adjusted model, calcium channel blockers also were statistically significantly associated with higher baseline serum 25(OH)D concentrations (P = 0.02) (Supplemental Table 2 ).
Of 2753 participants included in the baseline analysis, 566 were excluded from the response analysis: 494 failed run-in [including 97 whose baseline serum 25(OH)D measurement was <12 ng/mL], and a further 72 randomly assigned participants did not have a 1-y blood draw ( Figure 1 ). Optimal adherence was achieved by 1767 (81%). Of the 420 with suboptimal adherence, 228 (10% of the total) reported taking <80% of the pills, on average; 223 (10%) reported periods of $1 wk without taking pills; 73 (3%) had taken personal vitamin D supplements <400 IU/d; 30 (1%) had taken between 400 and 1000 IU/d; 4 had taken large doses (up to 50,000 IU/wk for a limited period); and 1 failed to report pill intake during the year 1.
After 1 y of supplementation, the unadjusted mean serum 25(OH)D concentration for those randomly assigned to 1000 IU cholecalciferol/d increased by 6.3 ng/mL, from 24.6 to 30.9 ng/mL. For those randomly assigned to calcium only or placebo, the mean serum 25(OH)D concentration fell by 1.1 ng/mL, from 24.5 to 23.4 ng/mL (data not shown), yielding a relative increase of 7.4 ng/mL, just over 1 SD of baseline concentrations, attributable to cholecalciferol supplementation.
In the multivariable model of serum response to supplementation, a greater proportional increase in serum 25(OH)D concentration in the vitamin D group relative to placebo was associated with lower baseline serum 25(OH)D, being female, season of each blood draw, wearing long pants and sleeves during sun exposure, moderate activity level, optimal adherence to study-pill intake, and use of personal vitamin D-containing supplements during the trial; these factors explained 50% of the variability in the serum response in 2157 individuals (R 2 , Table  3 ). To illustrate how the model for all participants might be interpreted, consider an example in which an individual with a median baseline serum 25(OH)D concentration (23.2 ng/mL) could expect a 33% (7.6 ng/mL) relative increase after supplementation, to an adjusted year 1 value of 30.8 ng/mL. In post hoc analysis, we explored the unexpected finding that sex was associated with serum response to vitamin D supplementation by adding body weight to the final model. Weight did not contribute significantly to the model, nor did it materially alter the coefficients for sex in the model.
A model developed for the subsample of optimally adherent participants was similar to the overall model (Supplemental Table  3 ), except that race was included in the model, whereas physical activity did not contribute significantly; use of personal vitamin D supplements could not be included because of the optimal adherence restriction. Significant univariate SNP analyses in baseline and response models restricted to non-Hispanic whites are shown in Supplemental Tables 4 and 5. The serum 25(OH)D concentration was significantly associated with rs10741657 in cytochrome P450 family 2 subfamily R member 1 (CYP2R1; P = 0.0003), and rs4588 in the vitamin D binding protein (GC; P < 0.0001). However, inclusion of these variables in the final multivariable model barely changed the R 2 from 0.28 to 0.29 and had a substantial impact only on the coefficients for smoking status (Supplemental Table 4 ).
When we examined serum response to vitamin D supplementation (Supplemental Table 5 ), only the rs10766197 polymorphism of CYP2R1 contributed significantly (P = 0.001), but, again, this did not affect the R 2 value of 0.48 (Supplemental Table 5 ) or the coefficients of the other variables. When we restricted to optimally adherent participants, 3 polymorphisms contributed significantly to the final model: rs10766197 in CYP2R1 (P = 0.01), rs1801725 in the calcium-sensing receptor (CASR; P = 0.02), and rs4516035 in the vitamin D receptor (VDR; P = 0.04) (Supplemental Table 6 ). Inclusion of these variables in the model marginally increased R 2 from 0.49 to 0.51 (Supplemental Table 6 ).
In crude analyses of individuals who had not been taking vitamin D supplements before the study or during year 1, we also assessed changes in proportions of individuals in the categories of inadequate (12 to <20 ng/mL) and adequate ($20 ng/mL) serum 25(OH)D concentrations (7) (Figure 2) . After 1 y, adequate concentrations were seen in 89% of participants who had received 1000 IU cholecalciferol/d and in 54% of controls. In stratified analyses, 83% of those who began with inadequate concentrations reached adequacy after 1 y of supplementation compared with 30% of controls. Among those who began the study with adequate concentrations, 94% of those randomly assigned to vitamin D were still adequate at 1 y compared with 72% of controls. These figures were similar in participants with optimal adherence (data not shown).
Discussion
We modeled the determinants of serum 25(OH)D response to supplementation with 1000 IU cholecalciferol/d after 1 y of treatment in a large randomized trial in 2187 men and women aged 45-75 y, from 11 geographically diverse regions of the United States. At baseline, 17 factors were independently associated with baseline serum 25(OH)D concentrations, but we found that 50% of the variability in an individualÕs response to supplementation could be explained by baseline serum 25(OH)D concentration and just a few other factors. A greater proportional serum response was seen with a lower baseline serum 25(OH)D concentration, being female, optimal adherence, [21] 274 [25] 286 [26] 192 [22] 225 [25] TABLE season of baseline and year 1 blood draws, wearing pants and sleeves when out in the sun, physical activity, and personal vitamin D supplement intake beyond that prescribed. The rs10766197 polymorphism of CYP2R1 was significantly associated with serum response in non-Hispanic whites, but it did not improve the explanatory value (R 2 ) of the multivariable model. Although our model confirmed the findings of others that response to supplementation varies with season of blood collection and baseline serum 25(OH)D concentration (27, 42) , other aspects of the analysis were unexpected. For example, we found a significantly greater proportional serum 25(OH)D concentration increase from supplementation in women than in men, a finding that, to our knowledge, has not been reported in other trials (5, 21, 27, 43, 44) . We may have seen this result because our sample size was very large and we could adjust for many potential confounders. Our results also contrast with studies that reported a significant association between response to supplementation and BMI (27) , including a systematic review suggesting that the dose per kilogram of body weight explains 34.5% of the serum response (28) . Although BMI affected baseline serum 25(OH)D concentrations, it did not independently affect the serum response to supplementation in our study. Other studies provide mixed or limited evidence that response to supplementation is associated with calcium intake, estrogen use, and dietary fat (27) , but our results supported none of these associations. The inconsistencies seen across studies may reflect small sample sizes, as well as differences in the covariates collected and how they were measured. Age and race were not associated with response to supplementation in our study or in several others (21, 27, (45) (46) (47) (48) (49) (50) (51) . Several variables (being female, greater physical activity, wearing long pants and sleeves while outdoors, and personal vitamin D supplement use) contributed significantly to both baseline and response models; this suggests either that these factors are independent determinants of both baseline serum 25(OH)D concentration and response to supplementation, or that they have residual effects in the response model because they are imperfectly represented by baseline serum 25(OH)D concentration, e.g., because of measurement error. Similarly, some other predictors in the response model are correlated-e.g., seasons of baseline and year 1 blood draws and baseline serum 25(OH)D concentration and physical activity-yet they contributed independently to the final model. It is possible that some of the variability between studies in the predictors of response to supplementation may be due to the intercorrelation of such variables and the impact of collinearity in model building. Overall, our model for baseline concentrations contained 17 factors that explained 32% of the variability in baseline serum 25(OH)D. We confirmed the observations of others that baseline concentrations reflect a variety of personal characteristics; nutritional, behavioral and lifestyle factors; and measures of sun exposure (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) 42) . Our finding of an association between glucocorticoid use and lower serum 25(OH)D concentrations adds to mixed evidence from previous studies. Furthermore, it is unclear whether there is a biological basis for the association, or if confounding by comorbid illness accounts for it; the latter possibility is supported by a small meta-analysis that showed significantly lower serum 25(OH)D in patients treated with glucocorticoids than in healthy controls, but not in diseased controls (52, 53) . Our finding that hormone replacement therapy was associated with significantly higher serum 25(OH)D baseline concentrations is supported by Cheng et al. (54) in univariate but not multivariable models. Alcohol intake was independently associated with higher baseline serum 25(OH)D MET-min/wk. Low: less than moderate activity level. 5 Sex-specific quartiles were used in nutrition analyses. 6 Cutoffs for quartiles-men: 0.6, 1.0, and 1.7; women: 0.5, 1.0, and 1.5. jn.nutrition.org concentrations in our study, whereas the evidence from other studies is mixed (15, (55) (56) (57) (58) (59) . Surprisingly, we found that sunscreen use was associated with slightly higher serum 25(OH)D concentrations; this may be because individuals who regularly use sunscreen have greater sun exposure, but may use sunscreen ineffectively (7, 60) . In contrast, individuals who regularly wore long pants and long sleeves outdoors had lower concentrations of serum 25(OH)D, a finding that may relate to more effective sun protection, or may reflect confounding by other factors. Incorporation of selected genetic variants in the full baseline and response models extended our previous work in minimally adjusted models (31) . Although the association between rs10766197 and serum response is consistent with our previous results (31), 2 polymorphisms (rs6013897 and rs7968585) that contributed significantly to the minimally adjusted model did not do so in the full model. Furthermore, the inclusion of genetic information in the full model in non-Hispanic whites did not substantially improve the R 2 value of the model (R 2 = 48%). The finding that genetic factors may have only a small impact on serum response is supported by some research (43) , but not all (42) . However, even if the impact of the genetic variants appears to be relatively small overall, there may be cumulative effects in individuals with multiple risk alleles (61) . In the baseline model, our findings implicating rs10741657 in CYP2R1 and rs4588 (a missense mutation) in GC are largely consistent with other reports (30, 42, 43, 61, 62) . In optimally adherent participants, our findings implicating rs4516035 in VDR and rs1801725 (a missense mutation) in CASR appear to be novel and merit further investigation. Recent evidence also suggests that DNA methylation in CYP2R1 and cytochrome P450 family 24 subfamily A member 1 (CYP24A1) may be associated with poorer response to vitamin D supplementation (63); we could not address this question in our study. Ideally, a more comprehensive examination of rare and common variations in the genome will be necessary to further our understanding.
In a crude analysis of participants who had not been taking vitamin D supplements before enrollment or during year 1 of the study, adequate concentrations of serum 25(OH)D ($20 ng/mL) (7) were found after 1 y in 89% of those randomly assigned to 1000 IU cholecalciferol daily, as well as in 54% of controls. The NAMÕs RDA [defined as the intake likely to ''meet or exceed the needs of about 97.5% of the population'' (7)] is 600 and 800 IU/d for those aged #70 and >70 y, respectively. Supplementation with 1000 IU/d did not meet the NAM target in our participants, a finding that is consistent with the assertion that the RDA may not achieve its target in the general population (64, 65) . However, this finding was not adjusted for potential confounding (e.g., by season), and our population had special characteristics that may affect generalizability, including a history of colorectal adenoma (but not familial polyposis syndromes), the exclusion of vitamin D-deficient participants (serum 25(OH)D concentration <12 ng/mL), a lower prevalence of minorities (18% compared with 28%), and a higher prevalence of overweight participants (78% compared with 72%) than in the general population (66, 67) .
Our models account for 32% and 50% of the variability in baseline serum 25(OH)D and the response to supplementation, respectively. The unexplained variability may relate to differences in absorption, metabolism, and genetic factors, which we could not address in this study. Predictions from our overall model are consistent with those of others. For example, 1000 IU/d is expected to increase a baseline serum 25(OH)D of 30 to 38 ng/mL in GarlandÕs model (68) and to 39 ng/mL in ours, although in our model, optimal adherence increases the postsupplementation concentration to 42 ng/mL. This difference is not unexpected, but illustrates the importance of adherence as a source of error in dose-response estimation during long-term supplementation. Perhaps not surprisingly, there is considerable variation within (5) and between (69) studies in the slope representing the increase in serum 25(OH)D concentration after vitamin D supplementation. Relative to other studies (69), we observed only a modest mean increase in serum 25(OH)D concentration of 6.3 ng/mL after supplementation with 1000 IU cholecalciferol/d, and a decrease of 1.1 ng/mL in controls. Several study-related factors may have affected these changes: 1) more than one-half of participants were taking vitamin D supplements at baseline, and they agreed to stop doing so; 2) participants were counseled to avoid excessive vitamin D and calcium intake during the study; and 3) three-quarters of our participants were overweight or obese, and so would expect a smaller effect than that seen in other studies (69) .
Strengths of our study include the large sample size, inclusion of racial and ethnic minorities of both sexes, availability of detailed personal data, good adherence to pill intake, and detailed information on lapses in pill intake and use of personal vitamin D supplements (which occurred in <5% of participants). We avoided bias that could have resulted from regression to the mean by examining relative proportional increases in our models, comparing those receiving supplements or placebo. Limitations of the study include factors affecting generalizability, such as our enrollment of individuals with colorectal polyps and our counseling of participants to avoid excessive dietary intake of calcium and vitamin D during the study.
In this large, multicenter chemoprevention trial, we found that 50% of the variability in serum response to supplementation with 1000 IU cholecalciferol/d was explained by 8 factors: baseline serum 25(OH)D concentration, sex, optimal adherence, season, use of long pants and long sleeves for protection from the sun, physical activity level, and personal vitamin D supplementation. In contrast to previous smaller studies, we identified a significantly higher response to supplementation in women than in men. Associations were identified with several genetic factors that merit further investigation.
